Repaglinide

Description

The following has been updated from the pre solicitation that was issued on August 21, 2020. A contract resulting from this solicitation will establish a national supply source, in accordance with FAR 52.216-21 (Requirements), to provide the items listed in the schedule for purchase by Department of Defense only through the DLA prime vendor programs. The Defense Logistics Agency is planning to issue a solicitation for a DoD only national requirements contract for Repaglinide Tablets. Procurement details follow. Repaglinide 0.5MG, 1MG and 2MG in 100 count bottles. This will be an unrestricted and fully competitive acquisition. The contract will be a firm-fixed price, requirements type contract with a one year base and four one year options. A contract resulting from this solicitation will establish a national supply source, in accordance with FAR 52.216-21 (Requirements), to provide the items listed in the schedule for purchase by Department of Defense through the DLA prime vendor program. The annual usage estimates will be provided in the Schedule of Supplies section of the solicitation. This is a commercial item and will be solicited using FAR part 12. All sources may submit a proposal which shall be considered by the agency. A copy of the solicitation will be posted to the DLA Bid Board System (DIBBS) at https://www.dibbs.bsm.dla.mil and Beta Sam.Gov at https://beta.sam.gov. Interested parties should contact Phyllis Daraio (215-737-7941) email (phyllis.daraio@dla.mil) for any questions/comments. Interested parties are further advised to set up automated notifications of pre-solicitation or solicitation changes through this website. The current projected solicitation date is September of 2020. DLA reserves the right to issue the solicitation before or after the projected solicitation date.